Hainan Honz Pharmaceutical Co (300086) - Total Liabilities
Based on the latest financial reports, Hainan Honz Pharmaceutical Co (300086) has total liabilities worth CN¥824.00 Million CNY (≈ $120.58 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Hainan Honz Pharmaceutical Co asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Hainan Honz Pharmaceutical Co - Total Liabilities Trend (2007–2025)
This chart illustrates how Hainan Honz Pharmaceutical Co's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 300086 asset base.
Hainan Honz Pharmaceutical Co Competitors by Total Liabilities
The table below lists competitors of Hainan Honz Pharmaceutical Co ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Tongli Transmission Technology Co. Ltd. A
SHE:301255
|
China | CN¥511.87 Million |
|
China BlueChemical Ltd
F:H1Q
|
Germany | €4.87 Billion |
|
Shenzhen Hifuture Electric
SHE:002168
|
China | CN¥743.85 Million |
|
BRBI BR Partners S.A. ADSs
NASDAQ:BRBI
|
USA | $17.65 Billion |
|
Beijing LabTech Instruments Co Ltd
SHG:688056
|
China | CN¥113.93 Million |
|
Zhejiang Heda Technology Co Ltd
SHG:688296
|
China | CN¥328.22 Million |
|
Benz Mining Corp
F:1VU
|
Germany | €4.71 Million |
|
Nepes Corporation
KQ:033640
|
Korea | ₩458.11 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Hainan Honz Pharmaceutical Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Hainan Honz Pharmaceutical Co net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.95 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hainan Honz Pharmaceutical Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hainan Honz Pharmaceutical Co (2007–2025)
The table below shows the annual total liabilities of Hainan Honz Pharmaceutical Co from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥869.79 Million ≈ $127.28 Million |
+7.31% |
| 2024-12-31 | CN¥810.53 Million ≈ $118.61 Million |
+2.91% |
| 2023-12-31 | CN¥787.60 Million ≈ $115.25 Million |
-15.58% |
| 2022-12-31 | CN¥932.96 Million ≈ $136.52 Million |
+3.07% |
| 2021-12-31 | CN¥905.14 Million ≈ $132.45 Million |
-10.55% |
| 2020-12-31 | CN¥1.01 Billion ≈ $148.08 Million |
+70.76% |
| 2019-12-31 | CN¥592.59 Million ≈ $86.72 Million |
+12.47% |
| 2018-12-31 | CN¥526.90 Million ≈ $77.10 Million |
+67.10% |
| 2017-12-31 | CN¥315.31 Million ≈ $46.14 Million |
-0.48% |
| 2016-12-31 | CN¥316.83 Million ≈ $46.36 Million |
+27.63% |
| 2015-12-31 | CN¥248.25 Million ≈ $36.33 Million |
+102.67% |
| 2014-12-31 | CN¥122.49 Million ≈ $17.92 Million |
+29.80% |
| 2013-12-31 | CN¥94.36 Million ≈ $13.81 Million |
-0.70% |
| 2012-12-31 | CN¥95.02 Million ≈ $13.91 Million |
-14.22% |
| 2011-12-31 | CN¥110.77 Million ≈ $16.21 Million |
+45.73% |
| 2010-12-31 | CN¥76.01 Million ≈ $11.12 Million |
+41.83% |
| 2009-12-31 | CN¥53.60 Million ≈ $7.84 Million |
-4.17% |
| 2008-12-31 | CN¥55.93 Million ≈ $8.18 Million |
+117.75% |
| 2007-12-31 | CN¥25.68 Million ≈ $3.76 Million |
-- |
About Hainan Honz Pharmaceutical Co
Honz Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pediatric medicines in China and internationally. It operates through Pharmaceutical Manufacturing and Sales; and Daily Necessities Manufacturing and Sales segments. The company offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal, cough … Read more